“For pancreatic cancer patients, tolerance of the chemotherapy is often low because of debility and nausea and vomiting in these patients who may have had abdominal surgery and have malabsorption. AZT’s TransT3 and TPD platforms for delivery of T3s have the potential to circumvent the issue of malabsorption of chemotherapies.”

“T3s delivered using AZT’s TransT3 and TPD platforms have the potential to provide a specific type of opportunity in treatment of human pancreatic cancer. A growing body of evidence has shown cancer stem cells within a tumor may give rise to therapy resistance and metastasis. Recent studies have shown that T3 treatment inhibits the growth of pancreatic cancer stem cells. Assessment of AZT’s TransT3 and T3 prodrugs impact on pancreatic cancer stem cells in preclinical studies has the potential to provide a valuable new opportunity to impact pancreatic cancer mortality.”

Dr. Richard Pestell AO
MD, PhD, MBA, FACP, FRACP, world-renowned cancer research scientist and physician and Member of AZT’s Scientific Advisory Board

“The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. …growing geriatric population is also expected to drive the growth during the forecast period.”